Comstock Metals Ltd

Clazakizumab, targeting IL-6, failed to meet primary efficacy outcomes in the IMAGINE Phase 3 trial for chronic active antibody-mediated rejection in kidney transplant recipients, according to a final analysis. No significant difference in kidney function was observed between clazakizumab and placebo, with no safety concerns reported.

AusBiotech 2024 will feature over 260 speakers and 60 sessions, addressing global biotech trends, research, and industry advancements. Key topics include artificial heart technology, quantum computing in biotech, and medical manufacturing. The event also highlights emerging biotechnologies in agriculture and cell and gene therapies, supported by government initiatives and strategic partnerships. Australia's biotech sector is rapidly advancing, driven by innovation, government support, and strategic geographical clustering near research institutions.

The AusBiotech 2024 Conference, spanning October 29 to November 1, features over 260 speakers and 60 sessions, focusing on advancing the biotech sector. Keynotes include Federal Minister Mark Butler, Victorian Minister Natalie Hutchins, and Dr. Daniel Timms on artificial hearts. The conference also includes the AgriBiotech and Biosecurity Summit, Cell and Gene Summit, and a Gala Dinner themed 'Life Science in Space'.

Otsuka's anti-APRIL antibody sibeprenlimab showed significant reduction in uPCR in a phase 3 trial for IgA nephropathy, prompting potential FDA submission. Final results expected in 2026. Competitors include Novartis' zigakibart, Vertex's povetacicept, and Vera's atacicept.

Swissmedic grants temporary marketing authorization for FILSPARI, a treatment for primary IgA nephropathy, based on results from the Phase 3 PROTECT Trial. FILSPARI offers a once-daily, oral, non-immunosuppressive treatment, potentially replacing RASi in patients with IgAN.

Pfizer's Hympavzi, a once-weekly injection for hemophilia A or B, received FDA approval. The drug, administered via auto-injector, aims to reduce bleeding episodes and treatment burden. Sales are projected to reach $300 million by 2030.

Cochin Shipyard Limited (CSL) is recruiting for Assistant Engineer (Mechanical, Electrical, Electronics, Maintenance), Assistant Administrative Officer, Assistant Fire Officer, and Accountant. Applications close on October 30, 2024. Candidates must be under 45 years old by this date. The basic pay is Rs 28,000 with additional allowances totaling Rs 55,384. An application fee of Rs 700 is required. The selection process includes an online test (Objective and Descriptive) and a PowerPoint presentation on work experience. Minimum passing marks vary by category.

Kurma Partners raised EUR 140 million in the first closing of Biofund IV, targeting EUR 250 million total. The fund aims for 16-20 new investments, focusing on innovative therapeutics. Three initial investments have been made, and the fund leverages Kurma's networks for success.

Kurma Partners raised €140m for Biofund IV, targeting €250m by 2025. Focused on innovative therapeutics, it aims for 16-20 investments, including SciRhom, Memo Therapeutics, and Avidicure. Kurma's model, proven by Amolyt Pharma, Emergence Therapeutics, and Corlieve Therapeutics acquisitions, attracted investors like Eurazeo, Bpifrance, and CSL.

MTPConnect opens $28.5 million funding for heart disease and diabetes drug/device development, inviting Australian spin-outs, start-ups, and SMEs to apply by 4 November 2024. Up to $1.5 million available per project, with co-contribution required. Benefits include mentorship and industry connections.